Document is current
Any future updates will be listed below
-
Authors
Goto, Tatsunori
Okamura, Hiroshi
Ikeda, Takashi
Mori, Yasuo
Shiratori, Souichi
Fujiwara, Shin-ichiro
Doki, Noriko
Matsuoka, Ken-ichi
Katayama, Yuta
Chen, Yi-Bin
Fløisand, Yngvar
Rossiter, Guillermo
Jansson, Johan
Nakaya, Ryou
Teshima, Takanori https://orcid.org/0000-0002-0941-271X
-
Funding
Funding for this research was provided by:
Takeda
- License Information
-
More Information
Article History
Received: 27 September 2024
Revised: 14 February 2025
Accepted: 16 February 2025
First Online: 12 March 2025
Declarations
:
: Souichi Shiratori has received research funding from Nippon Shinyaku. Noriko Doki has received consulting fees from Janssen Pharmaceutical KK; reports lectures/presentations/serving on speaker bureaus for AbbVie GK, Asahi Kasei Pharma KK, Astellas Pharma Inc., AstraZeneca KK, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Janssen Pharmaceutical KK, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Nippon Shinyaku Co., Ltd., Novartis Pharma KK, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi KK, Shionogi & Co., Ltd., and Takeda Pharmaceutical Company Limited. Ken-ichi Matsuoka has received honoraria from Astellas, Janssen, and Novartis. Yi-Bin Chen reports serving as a consultant for Alexion, Daiichi, Editas, Incyte, Novartis, Novo Nordisk, Pharmacosmos, Phesi, Takeda, and Vor. Yngvar Fløisand has served on advisory boards for Celgene, Novartis, Otsuka, Pfizer, and Takeda; received honoraria from Celgene, Novartis, Pfizer, and Takeda; received travel grants from AbbVie, Celgene, Novartis, and Takeda; and consulting fees from AbbVie, Arog, and Dava Oncology. Guillermo Rossiter and Johan Jansson are former employees of Takeda and hold stock and/or share options in Takeda. Ryou Nakaya is an employee of Takeda and holds stock and/or share options in Takeda. Takanori Teshima has received research funding from Asahi Kasei Pharma, Astellas, Chugai, Eisai, Fuji Pharma, Kyowa Kirin, Luca Science Inc., Nippon Shinyaku, ONO, Otsuka, Priothera SAS, Sanofi, SHIONOGI, and Sumitomo Pharma; received honoraria from AbbVie, Bristol Myers Squibb, Celgene, Kyowa Kirin, and Merck Sharp & Dohme; served on advisory boards for Merck Sharp & Dohme, Novartis, and Takeda; and received non-financial support from AstraZeneca, Daiichi Sankyo, Janssen, Meiji Seika Pharma, Novartis, and Roche Diagnostics. Tatsunori Goto, Takashi Ikeda, Yasuo Mori, Hiroshi Okamura, Shin-ichiro Fujiwara, and Yuta Katayama have no conflicts of interest to declare.
